GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressure

Foundayo launches connected April 6 astatine the aforesaid terms arsenic Novo's pill, threatening to reshape the $50 cardinal obesity cause marketplace earlier Novo's first-quarter results

Eli Lilly and Co (NYSE:LLY) has won FDA support for Foundayo, its oral GLP-1 weight-loss drug, with a commercialized motorboat acceptable for April 6.

The approval, which Citi flagged arsenic a must-read improvement for Novo Nordisk (NYSE:NVO) investors, arrives astatine 1 of the astir hard moments successful Danish drugs giants caller past and opens a caller beforehand successful the conflict for the obesity market.

Foundayo, known generically arsenic orforglipron, volition beryllium priced astatine $149 a period for the cash-pay starter dose, matching Novo's Wegovy pill.

Patients connected commercialized security volition wage a $25 copay, rising to $50 nether Medicare Part D. Citi, which covers Novo Nordisk and maintains a Neutral standing connected the stock, said the oral GLP-1 contention is present afloat underway.

Label differences and planetary reach

The 2 pills are not identical successful presumption of safety. Foundayo carries a thyroid tumour boxed warning, arsenic does Wegovy, but it besides comes with further cause enactment restrictions that Novo's merchandise does not. Simvastatin dosing is capped astatine 20mg astatine the starter dose, usage with beardown CYP3A4 inhibitors is constricted to a 9mg maximum, and CYP3A4 inducers should beryllium avoided altogether.

Foundayo does, however, deficiency the 30-minute post-dose regularisation connected food, portion and different oral medications that applies to the Wegovy pill, a applicable vantage that could power diligent and prescriber preference.

On planetary ambitions, Lilly has filed successful 40 countries, against a much selective planetary rollout from Novo. Citi noted that Lilly whitethorn motorboat up of the Wegovy pill successful a fig of markets, resulting successful a meaningful commercialized headwind for Novo's planetary business.

Morgan Stanley flags a pugnacious archetypal quarter

The timing of Foundayo's accomplishment compounds unit that Morgan Stanley analysts had already identified up of Novo's first-quarter results.

In a enactment published connected Wednesday, the American concern bank, which holds an 'equal-weight' standing and a $40 terms people connected the ADR, said Q1 is apt to beryllium the hardest 4th of 2026 for Novo.

It pointed to a antagonistic terms and premix effect connected US Wegovy, driven by little injectable cash-pay prices, a higher proportionality of cash-pay patients and a debased mean terms for the pill, wherever astir patients stay connected starter doses.

Currency headwinds are expected to instrumentality 9% disconnected first-quarter income astatine the Morgan Stanley estimation level.

Morgan Stanley forecasts Wegovy pill income of $2 billion for the afloat twelvemonth and expects injectable publication volumes to retrieve to 330,000 a week successful the 2nd fractional of 2026 arsenic Medicare Part D sum opens up. The slope stands fractionally supra the apical extremity of Novo's ain guidance, projecting a income diminution of 4% successful changeless currency terms.